LakePharma and NJ Bio Form Strategic Alliance to Provide Streamlined Antibody-Drug Conjugate ServicesAdded On: 2020-02-11
LakePharma Announces Its 2019 Symposium AgendaAdded On: 2019-07-30
LakePharma Announces Expansion into the Dallas/Fort Worth MetroplexAdded On: 2019-07-23
Added On: 2014-10-09
LakePharma hosted its second annual Antibody Engineering Symposium at the South San Francisco Conference Center on October 9-10, 2014. 300 Bay Area experts in the field of Antibody Engineering attended, and participants included the Bay Area’s leading antibody engineering scientists representing AbbVie Therapeutics, Amgen, Bayer, Cell Marque, Cellerant, Genentech, Gilead, Igenica, Pfizer, Stanford, UCSF, Sutro, Trellis Bioscience, and several other biotech companies from the Bay Area and beyond.
The first day focused on antibody discovery and engineering techniques with a keynote address from Aaron Sato, V.P. of Research at Sutro BioPharma and included presentations from Rinat/Pfizer, UCSF, Stanford and OMT, Inc.
Day two was split into two sessions. The morning session focused on Products, Therapeutics and Pipeline with a keynote presentation from David Meininger, Executive Director at Merck. The afternoon focused on CMC and Manufacturing Strategies, with presentations from Amgen, OncoMed, Genentech and GE Life Sciences.
Feedback regarding the speaker presentations was positive. Click here for additional information.
Theme: Protein and Antibody Engineering
Dates: Thursday, October 9 and Friday October 10, 2014
Location: South San Francisco Conference Center
Aaron Sato, Ph.D.
Vice President of Research, Sutro Biopharma
David Meininger, Ph.D.
Executive Director, Merck
Xinfeng Zhang, Ph.D.
VP of CMC, Generon Corporation
Hua Tu, Ph.D.
Additional information on the conference can be found at www.lakepharma.com/AES2014.